arabinofuranosylcytosine triphosphate has been researched along with Recrudescence in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (30.00) | 18.7374 |
| 1990's | 5 (50.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ikeda, S; Kawai, K; Kiriyama, M; Kobayashi, S; Kurumiya, Y; Mizuno, K; Mori, M; Nakashima, Y; Oiwa, T; Sekoguchi, E; Tominaga, K; Torii, N; Watanabe, H | 1 |
| Cinatl, J; Hollatz, G; Koehl, U; Kornhuber, B; Kreuter, J; Mutschler, E; Rohrbach, E; Schwabe, D; Visschedyk, K | 1 |
| Bennett, J; Browman, GP; Goldberg, J; Kukla, C; Larson, RA; Miller, KA; Preisler, HD; Raza, A; Rustum, YM; Vogler, R | 1 |
| Estey, EH; Kantarjian, H; Keating, MJ; Plunkett, W; Rios, MB | 1 |
| Andreeff, HM; Beran, M; Estey, E; Gandhi, V; Kantarjian, HM; Koller, CA; Kornblau, SM; O'Brien, S; Plunkett, W | 1 |
| Heinemann, V; Jehn, U | 1 |
| Aul, CH; Büchner, T; Heinecke, A; Hiddemann, W; Maschmeyer, G; Schleyer, E; Uhrmeister, C | 1 |
| Danhauser, L; Gandhi, V; Iacoboni, S; Keating, M; Liliemark, J; Plunkett, W | 1 |
| Drenthe-Schonk, A; Haanen, C; Muus, P; Raymakers, R; Salden, M; Wessels, J | 1 |
| Browman, G; Preisler, HD; Raza, A; Rustum, Y | 1 |
2 review(s) available for arabinofuranosylcytosine triphosphate and Recrudescence
| Article | Year |
|---|---|
Rationales for a pharmacologically optimized treatment of acute nonlymphocytic leukemia with cytosine arabinoside.
Topics: Arabinofuranosylcytosine Triphosphate; Biological Transport; Cytarabine; Deamination; Drug Administration Schedule; Drug Resistance; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Phosphorylation; Recurrence | 1990 |
Studies on the cytotoxicity of cytosine arabinoside.
Topics: Adolescent; Adult; Arabinofuranosylcytosine Triphosphate; Bone Marrow; Cell Cycle; Cell Differentiation; Cells, Cultured; Clone Cells; Colony-Forming Units Assay; Cytarabine; DNA; Drug Resistance; Female; Granulocytes; Half-Life; Humans; Interphase; Kinetics; Leukemia; Male; Middle Aged; Phosphorylation; Recurrence | 1985 |
2 trial(s) available for arabinofuranosylcytosine triphosphate and Recrudescence
| Article | Year |
|---|---|
Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Cladribine; Cytarabine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Recurrence | 1996 |
High-dose versus intermediate-dose cytosine arabinoside in combination with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia--preliminary clinical and pharmacological data of a randomized comparison.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Cytarabine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Recurrence | 1990 |
6 other study(ies) available for arabinofuranosylcytosine triphosphate and Recrudescence
| Article | Year |
|---|---|
[A Case of Intrathecal Infusion of Methotrexate and Ara-C for a Patient with Meningitis Due to Recurrent Gastric Cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Biopsy; Chemotherapy, Adjuvant; Female; Gastrectomy; Humans; Meningitis; Methotrexate; Recurrence; Stomach Neoplasms | 2017 |
Pharmacology of intracellular cytosine-arabinoside-5'-triphosphate in malignant cells of pediatric patients with initial or relapsed leukemia and in normal lymphocytes.
Topics: Adolescent; Arabinofuranosylcytosine Triphosphate; Cell Line; Cell Line, Tumor; Child; Child, Preschool; Chromatography, High Pressure Liquid; Cytarabine; Half-Life; Humans; Infant; Inhibitory Concentration 50; Lymphocytes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence | 2007 |
Long-term outcome of patients with acute myelogenous leukemia: the role of maintenance therapy, consolidation therapy and the predictive value of two in vitro assays.
Topics: Arabinofuranosylcytosine Triphosphate; Cytarabine; Humans; In Vitro Techniques; Leukemia, Myeloid, Acute; Predictive Value of Tests; Prognosis; Recurrence; Remission Induction; Treatment Outcome; Tumor Stem Cell Assay | 1993 |
Treatment of relapsed or refractory AML with intermediate-dose arabinosylcytosine (ara-C): confirmation of the importance of ara-C triphosphate formation in mediating response to ara-C.
Topics: Adult; Aged; Arabinofuranosylcytosine Triphosphate; Clinical Protocols; Cytarabine; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid, Acute; Middle Aged; Recurrence; Remission Induction | 1993 |
Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in patients with relapsed leukemia.
Topics: Adult; Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Cytarabine; DNA Replication; Drug Evaluation; Female; Half-Life; Humans; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Vidarabine | 1987 |
The treatment of patients with acute nonlymphocytic leukemia in remission.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Cytarabine; Humans; Kinetics; Leukemia; Prognosis; Recurrence; Time Factors | 1985 |